{"url_path":"/sec/qttb/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/0001193125-26-304964-index.html","accession_number":"0001193125-26-304964","cik":"0001661998","ticker":"QTTB","issuer_name":"Q32 Bio Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1661998/0001193125-26-304964-index.html","primary_entity_key":"0001661998","primary_entity_name":"Q32 Bio Inc."},"word_count":120,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n 1.1\n  \n[Underwriting Agreement, dated July 14, 2026 by and among the Company and Morgan Stanley & Co. LLC, Jefferies LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc.](d150730dex11.htm)\n\n 4.1\n  \n[Form of Pre-Funded Warrant.](d150730dex41.htm)\n\n 5.1\n  \n[Opinion of Goodwin Procter LLP.](d150730dex51.htm)\n\n23.1\n  \n[Consent of Goodwin Procter LLP (included in Exhibit 5.1).](d150730dex51.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nQ32 Bio Inc.\n\nDate: July 15, 2026\n \n\n \nBy:\n \n\n/s/ Jodie Morrison\n\n \n\n \n\n \nJodie Morrison\n\n \n\n \n\n \nChief Executive Officer"}